JP6203740B2 - アルファ４ベータ７ヘテロ二量体特異抗体の投与 - Google Patents

アルファ４ベータ７ヘテロ二量体特異抗体の投与 Download PDF

Info

Publication number
JP6203740B2
JP6203740B2 JP2014543572A JP2014543572A JP6203740B2 JP 6203740 B2 JP6203740 B2 JP 6203740B2 JP 2014543572 A JP2014543572 A JP 2014543572A JP 2014543572 A JP2014543572 A JP 2014543572A JP 6203740 B2 JP6203740 B2 JP 6203740B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
days
specific antibody
heterodimer specific
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014543572A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505822A (ja
JP2015505822A5 (enExample
Inventor
ボリー，ドミニク
シュー，ハイリング
パン，ウェイ−チアン
リース，ウィリアム
サリヴァン，バーバラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2015505822A publication Critical patent/JP2015505822A/ja
Publication of JP2015505822A5 publication Critical patent/JP2015505822A5/ja
Application granted granted Critical
Publication of JP6203740B2 publication Critical patent/JP6203740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014543572A 2011-11-23 2012-11-21 アルファ４ベータ７ヘテロ二量体特異抗体の投与 Active JP6203740B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563430P 2011-11-23 2011-11-23
US61/563,430 2011-11-23
US201261599221P 2012-02-15 2012-02-15
US61/599,221 2012-02-15
PCT/US2012/066345 WO2013078375A2 (en) 2011-11-23 2012-11-21 Administration of alpha4beta7 hetero-dimer-specific antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017165395A Division JP6564435B2 (ja) 2011-11-23 2017-08-30 アルファ４ベータ７ヘテロ二量体特異抗体の投与

Publications (3)

Publication Number Publication Date
JP2015505822A JP2015505822A (ja) 2015-02-26
JP2015505822A5 JP2015505822A5 (enExample) 2016-01-21
JP6203740B2 true JP6203740B2 (ja) 2017-09-27

Family

ID=47291275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543572A Active JP6203740B2 (ja) 2011-11-23 2012-11-21 アルファ４ベータ７ヘテロ二量体特異抗体の投与
JP2017165395A Active JP6564435B2 (ja) 2011-11-23 2017-08-30 アルファ４ベータ７ヘテロ二量体特異抗体の投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017165395A Active JP6564435B2 (ja) 2011-11-23 2017-08-30 アルファ４ベータ７ヘテロ二量体特異抗体の投与

Country Status (7)

Country Link
US (1) US9914779B2 (enExample)
EP (2) EP2782599B1 (enExample)
JP (2) JP6203740B2 (enExample)
AU (1) AU2012340621B2 (enExample)
CA (1) CA2856866C (enExample)
MX (1) MX366936B (enExample)
WO (1) WO2013078375A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2890600T3 (es) 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
CA3154741A1 (en) * 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
BR112022013628A2 (pt) * 2020-01-10 2022-11-22 Protagonist Therapeutics Inc Métodos para tratar doenças inflamatórias intestinais com antagonistas de integrina alpha-4 beta-7
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN116482345B (zh) * 2023-06-16 2023-09-22 军科正源（北京）药物研究有限责任公司 用于检测双靶点药物受体占有率的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
JP2010521966A (ja) 2007-03-20 2010-07-01 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリンに結合するヒト化免疫グロブリンをコードする核酸
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
KR101346530B1 (ko) 2009-03-20 2013-12-31 암젠 인크 알파-4-베타-7 이종이량체 특이적 길항제 항체
EA201891433A3 (ru) 2010-01-15 2019-02-28 Кирин-Эмджен, Инк. Состав антитела и терапевтические режимы

Also Published As

Publication number Publication date
US20140322209A1 (en) 2014-10-30
WO2013078375A2 (en) 2013-05-30
JP6564435B2 (ja) 2019-08-21
US9914779B2 (en) 2018-03-13
MX366936B (es) 2019-07-31
EP2782599B1 (en) 2019-10-16
WO2013078375A3 (en) 2013-10-03
EP2782599A2 (en) 2014-10-01
CA2856866A1 (en) 2013-05-30
JP2018031780A (ja) 2018-03-01
EP3492099A1 (en) 2019-06-05
CA2856866C (en) 2022-07-12
JP2015505822A (ja) 2015-02-26
AU2012340621A1 (en) 2014-05-29
AU2012340621B2 (en) 2017-10-12
MX2014006265A (es) 2014-10-24

Similar Documents

Publication Publication Date Title
JP7416625B2 (ja) 早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
JP6564435B2 (ja) アルファ４ベータ７ヘテロ二量体特異抗体の投与
RU2571489C2 (ru) Способы выявления препаратов и аутоантител против tnf
JP6904905B2 (ja) 抗α４β７インテグリン抗体による治療の結果の予測
JP7080899B2 (ja) 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
KR101760465B1 (ko) Clec14a에 특이성을 갖는 신규한 항체 및 그 용도
AU2018378971A1 (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
JP2013527444A (ja) 抗体を検出するための方法
RU2679913C2 (ru) Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
JP2021531448A (ja) 抗薬物抗体（ａｄａ）免疫アッセイにおける薬物標的干渉を軽減するための方法
CN107459576A (zh) 用于诊断和治疗铁相关病症的组合物和方法
JP7331168B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
EA037032B1 (ru) Применение и способ для профилактики или лечения рака пищевода с использованием композиции, содержащей прогастрин-связывающее антитело
EA037027B1 (ru) Применение и способ для профилактики или лечения рака желудка с использованием композиции, содержащей моноклональное прогастринсвязывающее антитело
US20150132744A1 (en) Methods of detecting cells latently infected with hiv
US20110104153A1 (en) Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
CN119667163B (zh) Il-1r2在鉴定对象免疫状态中的应用
KR20140044769A (ko) 생물학적 약물을 사용한 환자의 치료를 최적화하는 방법
CA3016098C (en) Clinical assessment of m-protein response in multiple myeloma
EA050244B1 (ru) Способ диагностики in vitro рака желудка и способ мониторинга эффективности его лечения
EA050277B1 (ru) Способ диагностики in vitro рака пищевода и способ мониторинга эффективности его лечения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170830

R150 Certificate of patent or registration of utility model

Ref document number: 6203740

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250